Flagship Ventures Fund V General Partner LLC
Known title: 10% OwnerCIK: 0001724575
Associated companies
Transaction History
| SANA | ▼ Sell | Open Market | 22,760 | $142K | 6/7/2023 | View on chart |
| SANA | ▼ Sell | Open Market | 177,240 | $1.1M | 6/7/2023 | View on chart |
| SANA | ▼ Sell | Open Market | 181,461 | $1.1M | 6/6/2023 | View on chart |
| SANA | ▼ Sell | Open Market | 22,297 | $141K | 6/6/2023 | View on chart |
| SANA | ▼ Sell | Open Market | 9,330 | $58K | 5/26/2023 | View on chart |
| SANA | ▼ Sell | Open Market | 72,670 | $452K | 5/26/2023 | View on chart |
| SANA | ▼ Sell | Open Market | 102,245 | $649K | 5/25/2023 | View on chart |
| SANA | ▼ Sell | Open Market | 13,127 | $83K | 5/25/2023 | View on chart |
| SANA | ▼ Sell | Open Market | 308,290 | $2.0M | 5/24/2023 | View on chart |
| SANA | ▼ Sell | Open Market | 39,580 | $260K | 5/24/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Sana Biotechnology Featured in Diabetes Treatment Analysis
Sana Biotechnology was the subject of a recent analysis titled 'A Shot At Diabetes,' which likely examines the company's potential in treating the condition. This coverage places the stock in the spotlight for investors watching biotech developments. The stock is currently trading near its support level, with an RSI indicating it may be oversold.
Sana Biotechnology Featured in Diabetes Treatment Analysis. Sana Biotechnology was the subject of a recent analysis titled 'A Shot At Diabetes,' which likely examines the company's potential in treating the condition. This coverage places the stock in the spotlight for investors watching biotech developments. The stock is currently trading near its support level, with an RSI indicating it may be oversold.